Biodesix, Inc. (NASDAQ:BDSX) Director Hany Massarany Purchases 130,434 Shares

Biodesix, Inc. (NASDAQ:BDSXGet Rating) Director Hany Massarany purchased 130,434 shares of the company’s stock in a transaction that occurred on Monday, November 21st. The stock was bought at an average price of $1.15 per share, with a total value of $149,999.10. Following the purchase, the director now owns 137,934 shares of the company’s stock, valued at approximately $158,624.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Biodesix Stock Down 7.1 %

Shares of NASDAQ:BDSX opened at $1.30 on Tuesday. The company has a current ratio of 0.64, a quick ratio of 0.64 and a debt-to-equity ratio of 1.12. The company has a fifty day simple moving average of $1.25 and a 200 day simple moving average of $1.64. The firm has a market cap of $54.72 million, a PE ratio of -0.75 and a beta of 1.14. Biodesix, Inc. has a 12-month low of $0.96 and a 12-month high of $7.20.

Biodesix (NASDAQ:BDSXGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.02). The company had revenue of $11.11 million during the quarter, compared to the consensus estimate of $10.90 million. Biodesix had a negative return on equity of 723.65% and a negative net margin of 162.97%. On average, equities research analysts anticipate that Biodesix, Inc. will post -1.51 EPS for the current fiscal year.

Institutional Trading of Biodesix

A number of hedge funds and other institutional investors have recently made changes to their positions in BDSX. Endurant Capital Management LP bought a new stake in shares of Biodesix in the first quarter worth $221,000. Allworth Financial LP bought a new stake in Biodesix during the second quarter valued at $92,000. Renaissance Technologies LLC bought a new stake in Biodesix during the second quarter valued at $93,000. Essex Investment Management Co. LLC bought a new stake in Biodesix during the third quarter valued at $480,000. Finally, Vanguard Group Inc. increased its stake in Biodesix by 33.1% during the third quarter. Vanguard Group Inc. now owns 239,656 shares of the company’s stock valued at $305,000 after purchasing an additional 59,660 shares during the last quarter. Institutional investors own 53.48% of the company’s stock.

About Biodesix

(Get Rating)

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

Recommended Stories

Insider Buying and Selling by Quarter for Biodesix (NASDAQ:BDSX)

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.